Income Statement Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.49 USD | -2.46% |
|
+2.74% | +50.06% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M | |||||
Total Revenues | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M | |||||
Cost of Goods Sold, Total | 220M | 420M | 435M | 466M | 324M | |||||
Gross Profit | -187M | -368M | -399M | -408M | -257M | |||||
Selling General & Admin Expenses, Total | 71.1M | 90.31M | 116M | 126M | 184M | |||||
Other Operating Expenses, Total | 71.1M | 90.31M | 116M | 126M | 184M | |||||
Operating Income | -258M | -458M | -515M | -534M | -441M | |||||
Interest And Investment Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M | |||||
Net Interest Expenses | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M | |||||
Income (Loss) On Equity Invest. | -1.32M | -11.08M | -15.63M | - | - | |||||
EBT, Excl. Unusual Items | -258M | -461M | -481M | -486M | -412M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | -32.56M | -899K | |||||
Other Unusual Items | -10M | -13.48M | -100K | - | - | |||||
EBT, Incl. Unusual Items | -268M | -474M | -481M | -519M | -413M | |||||
Earnings From Continuing Operations | -268M | -474M | -481M | -519M | -413M | |||||
Net Income to Company | -268M | -474M | -481M | -519M | -413M | |||||
Net Income - (IS) | -268M | -474M | -481M | -519M | -413M | |||||
Net Income to Common Incl Extra Items | -268M | -474M | -481M | -519M | -413M | |||||
Net Income to Common Excl. Extra Items | -268M | -474M | -481M | -519M | -413M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | |||||
Basic EPS - Continuing Operations | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | |||||
Basic Weighted Average Shares Outstanding | 70.89M | 76.97M | 88.77M | 98.85M | 108M | |||||
Net EPS - Diluted | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | |||||
Diluted EPS - Continuing Operations | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | |||||
Diluted Weighted Average Shares Outstanding | 70.89M | 76.97M | 88.77M | 98.85M | 108M | |||||
Normalized Basic EPS | -2.27 | -3.74 | -3.39 | -3.08 | -2.37 | |||||
Normalized Diluted EPS | -2.27 | -3.74 | -3.39 | -3.08 | -2.37 | |||||
Supplemental Items | ||||||||||
EBITDA | -251M | -451M | -506M | -524M | -431M | |||||
EBITA | -258M | -458M | -515M | -534M | -441M | |||||
EBIT | -258M | -458M | -515M | -534M | -441M | |||||
EBITDAR | -235M | -428M | -473M | -486M | -367M | |||||
Normalized Net Income | -161M | -288M | -301M | -304M | -257M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 71.1M | 90.31M | 116M | 126M | 120M | |||||
Research And Development Expense From Footnotes | 230M | 420M | 435M | 466M | 389M | |||||
Net Rental Expense, Total | 16.24M | 22.47M | 33.4M | 37.51M | 64.41M | |||||
Stock-Based Comp., COGS (Total) | 26.71M | 56.28M | 82.21M | 94.23M | 49.44M | |||||
Stock-Based Comp., G&A Exp. (Total) | 20.3M | 35.12M | 51.84M | 60.04M | 30.78M | |||||
Total Stock-Based Compensation | 47.01M | 91.4M | 134M | 154M | 80.22M |
- Stock Market
- Equities
- NTLA Stock
- Financials Intellia Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















